Andreas Vogt joins Healthcare & Life Sciences arm of AlixPartners

AlixPartners has appointed Andreas Vogt as a Managing Partner in the firm’s Healthcare & Life Sciences practice in Zurich. He will leverage his more than twenty years of consulting and industry experience to support the firm’s healthcare and MedTech clients with transformations.

Prior to joining AlixPartners, Andreas Vogt worked at Deloitte where he was a Partner in the firm’s Swiss operation since 2014. He previously worked at Roland Berger for six years, rising to the role of Principal at the firm in its Pharma & Healthcare practice. Earlier roles include CEO of Imperial Healthcentre Munich for a year, from 2007; Assistant to board of directors at Sana Kliniken for a year, from 2006; as well as a resident physician in trauma surgery / orthopaedics at various clinics in southern Germany, starting in 2004.

Vogt holds a Master of Business administration from the University of Applied Scienes Deggendorf / University of California Los Angeles and a studied medicine at the Ludwig-Maximilians Universität München.

Vogt, in his new role as Managing Director in AlixPartners’ Zurich office, joins the firm’s Healthcare & Life Sciences practice. The position sees him take responsibility for supporting the firms’ MedTech and healthcare clients in the areas of performance improvement programs and large transformations.

Commenting on the appointment, Simon Freakley, Chief Executive Officer at AlixPartners, says, “He has substantial experience in this industry, both as a strategy consultant and as a physician, and I am confident that his expertise will prove invaluable as we continue to strengthen our European Healthcare & Life Sciences Practice.”

Beatrix Morath, Managing Director and Country Head Switzerland (she joined AlixPartners in 2014 from Roland Berger), says that the firm is “delighted” to welcome Andreas Vogt to the Swiss Healthcare & Life Sciences team. The move reflects, according to her, the firm's growing commitment to the Swiss market – the consulting market of Switzerland is estimated to be worth €943 million.

She adds, “He has worked in a variety of industry and consulting positions and has an excellent network. I am confident that Andreas will be an integral part in supporting clients within the Healthcare & Life Sciences field of business as we continue to grow.”